UCB reports interim Phase II data for rozanolixizumab in thrombocytopenia

UCB S.A. (Euronext:UCB) reported interim data from 28 patients with primary persistent or chronic immune thrombocytopenia (ITP) in a Phase II trial showing that subcutaneous rozanolixizumab (UCB7665) led to maximum mean reductions in total IgG levels of 43.6% at day 29 for the low dose and of 50.5% at day 22 for the high dose. Additionally, 53.3% of patients who received low-dose rozanolixizumab and 30.8% of patients who received high-dose rozanolixizumab achieved a platelet count of ≥50x10⁹ platelets/L. Rozanolixizumab was well tolerated with headache reported as the most common treatment-emergent adverse event.

Patients in the open-label, international trial received once-weekly 4 mg/kg rozanolixizumab for five weeks or once-weekly 7 mg/kg rozanolixizumab for three weeks. The trial's primary endpoint is safety. The data were reported in an abstract released ahead of the American Society of Hematology meeting in Atlanta in December 2017...